Eurofins Scientific (ERF) AI Stock Analysis

• Market Cap: €11.54B
• Dividend Yield: 0.91%
• Average Volume (3M): 294.43K
• Price to Earnings (P/E): 27.0
• Beta (1Y): 1.04
• Revenue Growth: 6.25%
• EPS Growth: 18.93%
• Country: FR
• Employees: 62,696
• Sector: Healthcare
• Sector Strength: 37
• Industry: Medical - Diagnostics & Research
• EPS (TTM): 1.64
• Shares Outstanding: 182,163,000
• 10 Day Avg. Volume: 247,553
• 30 Day Avg. Volume: 294,433
• PEG Ratio: 4.88
• Price to Book (P/B): 2.10
• Price to Sales (P/S): 0.00
• P/FCF Ratio: 13.36
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: €58.75
• Price Target Upside: -10.85% Downside
• Rating Consensus: Hold
• Number of Analyst Covering: 4

• Rating: 64 Neutral
• Price Target: €68.00 ▲(3.19%Upside)

Eurofins Scientific's overall stock score is primarily driven by strong financial performance and positive technical indicators. However, the high P/E ratio and overbought technical signals slightly detract from the potential attractiveness of the stock.

Eurofins Scientific Business Overview & Revenue Model

Company Description

Eurofins Scientific SE, together with its subsidiaries, provides various analytical testing and laboratory services worldwide. The company offers a portfolio of approximately 200,000 analytical methods to evaluate the safety, identity, composition, authenticity, origin, traceability, and purity of various products. It provides services such as agro-science, including biological assessment, consumer and human, and environmental safety, product chemistry, regulatory consultancy, and seed services; agro testing; assurance, such as product inspection, auditing, certification, training and consultation of food, consumer products, and healthcare and cosmetics; biopharma, and clinical diagnostics. In addition, the company offers consumer product testing, which include product compliance and audit, testing, certifications and approvals, inspections, training courses, and digital media and cyber security for various industries; cosmetics and personal care; environment testing, including water, air, soil, waste, and other products testing; and food and feed testing that include allergen, GMO, grain, meat, nano material, pesticides, and residual DNA testing. Further, it offers audit and certification, authenticity, carbohydrates, consulting, dioxins and POPs, food irradiation, labelling, law, heavy metals, identity preservation, mealtime, molecular and microbiology, mycotoxins, nutritional analyses, organic containments, packaging/migration, radioactivity, rapidest, sensorsy and consumer research, trainings, veterinary drug residues, and vitamins services. Additionally, the company provides forensic, genomic, maritime, materials and engineering, REACH, and technologies services. It operates approximately 900 laboratories in 54 countries. The company was founded in 1987 and is headquartered in Luxembourg City, Luxembourg.

How the Company Makes Money

Eurofins Scientific makes money primarily through its extensive network of laboratories that provide analytical testing services. The company generates revenue by offering specialized testing and support services to a diverse set of industries, including pharmaceuticals, food and feed testing, environment testing, and consumer product testing. Key revenue streams include fees for conducting laboratory tests, providing analytical tools and services, and offering consultancy services related to regulatory compliance and quality assurance. Eurofins also benefits from strategic acquisitions and partnerships, which expand its service offerings and geographic presence, contributing to its overall earnings.

Eurofins Scientific Financial Statement Overview

Summary

Eurofins Scientific is in a strong financial position with consistent revenue growth and profitability. Robust cash flow generation supports future growth opportunities, although slight leverage increase is noted.

Income Statement

Eurofins Scientific exhibits strong profitability with a gross profit margin consistently above 60%. The company demonstrated a notable revenue growth rate of 6.7% in 2024, recovering from a slight decline in 2023. However, EBIT for 2024 was missing, limiting assessment in that area. Net profit margin increased to 5.8% in 2024, indicating improving efficiency.

Balance Sheet

The balance sheet shows a solid equity base with an equity ratio of 49.0% in 2024, reflecting financial stability. However, the debt-to-equity ratio increased slightly to 0.68, which suggests a moderate level of leverage. Return on equity improved to 7.6% in 2024, indicating efficient use of equity capital.

Cash Flow

Eurofins Scientific's cash flow statement reflects robust operating cash flows, with an increase to €1.32 billion in 2024. The free cash flow to net income ratio is healthy, demonstrating strong cash generation relative to net income. Free cash flow grew significantly by 68.9% in 2024, highlighting improved liquidity and potential for reinvestment.

Breakdown	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	6.95B	6.51B	6.71B	6.72B	5.44B
Gross Profit	4.71B	620.40M	4.49B	4.57B	3.69B
EBITDA	1.38B	1.22B	1.36B	1.71B	1.28B
Net Income	406.40M	310.30M	610.20M	782.60M	539.40M
Balance Sheet
Total Assets	10.89B	10.89B	10.08B	9.33B	8.58B
Cash, Cash Equivalents and Short-Term Investments	613.90M	1.22B	486.60M	515.30M	912.40M
Total Debt	3.61B	3.93B	3.33B	2.75B	3.15B
Total Liabilities	5.50B	5.75B	5.23B	4.66B	4.86B
Stockholders Equity	5.34B	5.08B	4.78B	4.65B	3.69B
Cash Flow
Free Cash Flow	790.50M	467.80M	476.10M	990.30M	868.00M
Operating Cash Flow	1.32B	1.02B	1.14B	1.51B	1.22B
Investing Cash Flow	-846.50M	-681.10M	-855.90M	-1.03B	-525.00M
Financing Cash Flow	-1.09B	495.80M	-311.30M	-910.30M	-48.60M

Eurofins Scientific Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 65.90
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Negative
• STOCH: Negative

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For FR:ERF, the sentiment is Positive. The current price of 65.9 is above the 20-day moving average (MA) of 61.13, above the 50-day MA of 59.51, and above the 200-day MA of 51.67, indicating a bullish trend. The MACD of 1.15 indicates Negative momentum. The RSI at 81.76 is Negative, neither overbought nor oversold. The STOCH value of 87.74 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for FR:ERF.

Eurofins Scientific Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
ERF	64 Neutral	€11.54B	27.02	11.27%	0.91%	6.25%	18.93%
Sector *	52 Neutral	$7.61B	0.10	-63.03%	2.08%	16.34%	0.32%
0RUG	―	€14.42B	33.14	10.86%	0.74%	―	―
0MH6	―	€9.19B	26.10	8.89%	1.26%	―	―
0RG8	―	€16.82B	74.68	5.71%	0.40%	―	―
E8TN	―	€253.64M	62.33	2.27%	―	―	―
ZEP2	―		―		―	―	―